The review concluded that chronic opioid analgesic therapy exposure will lead to abuse/addiction in a small percentage of chronic pain patients, but a larger percentage will demonstrate aberrant drug-related behaviours and illicit drug use. The wide variation of drugs, populations and study designs used in the included studies means the authors' conclusions should be interpreted with caution.
Study selection
Studies that presented results for patients on chronic opioid analgesic therapy (for over one month and with a reported time interval for exposure) for chronic benign non-malignant pain were eligible for inclusion. Studies of tramadol or of any opioid antagonist were excluded. Studies of the prevalence of addiction/dependence within chronic pain patients were also excluded, as were studies that did not report the number of patients exposed to opioid therapy and studies that recruited patients suspected of opioid misuse. Levels of abuse/addiction, aberrant drug-related behaviours and urine toxicology measurements were the main outcomes of interest. A wide range of opioids/comparators and populations were studied.
The authors stated neither how the studies were selected for inclusion in the review nor how many reviewers performed the selection.
Assessment of study quality
Study quality was assessed independently by two reviewers who used 12 criteria (result was a percentage score) to examine issues such as sample size, allocation concealment, data collection methods, level of attrition and description of the population. Studies that scored less than 65% were not used to form conclusions. Disagreements were resolved by consensus.
Data extraction
Data were extracted by one author and checked by another.
